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Molecular imaging with engineered physiology
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In vivo imaging techniques are powerful tools for evaluating biological systems. Relating
image signals to precise molecular phenomena can be challenging, however, due to
limitations of the existing optical, magnetic and radioactive imaging probe mechanisms. Here
we demonstrate a concept for molecular imaging which bypasses the need for conventional
imaging agents by perturbing the endogenous multimodal contrast provided by the
vasculature. Variants of the calcitonin gene-related peptide artiﬁcially activate vasodilation
pathways in rat brain and induce contrast changes that are readily measured by optical and
magnetic resonance imaging. CGRP-based agents induce effects at nanomolar concentrations
in deep tissue and can be engineered into switchable analyte-dependent forms and
genetically encoded reporters suitable for molecular imaging or cell tracking. Such artiﬁcially
engineered physiological changes, therefore, provide a highly versatile means for sensitive
analysis of molecular events in living organisms.
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T
he combination of chemical probes with noninvasive
imaging-based detection uniquely enables molecular and
cellular phenomena to be mapped across large regions
of living tissue1. Molecular imaging agents enable in vivo
monitoring of a wide variety of discrete targets, such as
low-molecular weight analytes, protein receptors, enzymes
and metabolic processes. Applications range from basic
biological investigations to clinical evaluation of diseases, and
the use of molecular imaging techniques can be particularly
important for analysis of hard-to-reach structures such as
the brain.
Despite impressive progress, however, current molecular
imaging approaches remain limited by the available forms of
imaging probes. Radioactive probes are the current gold standard
for clinical molecular imaging, both in brain and in peripheral
tissue. These agents are detected with subnanomolar sensitivity
but relatively poor spatial resolution by positron emission
tomography (PET) and single photon computed tomography.
Although radiotracers have enabled a host of groundbreaking
imaging applications, they cannot be switched on and off by
targets or analytes. This increases their toxicity, rules out
biosensing approaches, and limits most dynamic measurements
to pharmacokinetic time scales on the order of minutes. Probes
for dynamic molecular magnetic resonance imaging (MRI) can be
imaged in animal brains at submillimetre resolution2. Their
potency can be dynamically modulated, but they are difﬁcult to
detect with sensitivity appropriate for most biological targets of
interest, in the nanomolar range3. Techniques such as nuclear
hyperpolarization4 and chemical exchange saturation transfer5
have been explored to boost the efﬁciency of MRI probe
detection; in some instances, these have been reported
to provide sensitivity to picomolar-scale targets in vitro6.
Micron-sized MRI contrast agents7 have been applied at
comparable concentrations in live animal brains, but have so
far been demonstrated primarily for cell tracking. Ultrasound and
diffuse optical molecular imaging techniques also show
promise8,9, but are still in early stages of development. The
need for continuing innovation of sensitive and versatile
molecular imaging strategies, therefore, persists.
To address this need, we sought to establish a molecular
imaging paradigm that can be applied in the brain and that
bypasses limitations of existing imaging agents by manipulating a
strong endogenous physiological contrast source rather than
employing exogenous agents that are themselves directly
measured. The vasculature is one of the most potent endogenous
contrast sources available to imaging modalities. Changes in
blood volume, ﬂow or oxygenation are robustly detectable by
MRI, optical and ultrasound-based noninvasive imaging, as well
as by PET, single photon computed tomography and X-ray
imaging performed in conjunction with intravascular tracers. The
vasculature densely permeates most tissues. In the cerebral cortex,
the mean distance from any point to a blood vessel is about 13 mm
(ref. 10). Vascular haemodynamic changes can be evoked by a
variety of chemical species, many of which act at nanomolar
concentrations.
We reasoned that a strategy for ‘hijacking’ vascular
physiology to report on speciﬁc molecular or cellular events
of interest by means of engineered vasoactive probes
could provide a sensitive new platform for molecular imaging.
In this paper, we demonstrate that this approach is feasible
and enables the construction of both analyte-responsive
molecular imaging agents and genetically encodable reporters.
Such molecular imaging methods based on engineering
of physiological contrast sources could offer a versatile
alternative to conventional contrast agents in scientiﬁc or clinical
contexts.
Results
Platform for vasoactive imaging agents. To demonstrate
the engineered haemodynamic imaging approach, we chose to
engineer calcitonin gene-related peptide (CGRP), the most potent
known human vasodilatory peptide11. Endogenous CGRP occurs
as two closely-related 37 residue isoforms that act on widely
expressed RAMP1 (receptor activity-modifying protein 1)/CLR
(calcitonin receptor-like receptor) receptor heterodimers to
induce dilation of intracerebral arterioles with a half-effective
concentration (EC50) below 10 nM (ref. 12). This suggests that
CGRP variants should be capable of artiﬁcially inducing
equivalents to the well-known blood oxygen level dependent
(BOLD) MRI response13 that constitutes the basis of most
functional brain imaging experiments (Fig. 1a). Molecular
imaging of arbitrary analytes could be possible if activation of
an initially blocked or caged CGRP analog could be coupled to
presence of the analyte (Fig. 1b). Finally, because CGRP is a
peptide, it could potentially be harnessed as a genetic reporter in
cells and tissues (Fig. 1c). CGRP, therefore, provides an excellent
basis for demonstrating the application of vasoactive molecules to
several major problems in molecular imaging.
Vasoprobe detection by in vivo optical imaging and MRI.
To determine the feasibility of imaging the action of CGRP, we
ﬁrst characterized in vivo vasodilation effects of wild-type human
a-isoform CGRP (wtCGRP) in the rat brain using optical imaging
and MRI. Optical imaging via a cranial window (Fig. 2a) permitted
direct visualization of the effects of dilation of both macroscopic
and microscopic blood vessels upon topical infusion of wtCGRP
(0.3ml, 50 nM) onto exposed cortex. Dilation of macroscopic
vessels was quantiﬁed as percent change in vascular diameter
(Fig. 2b red bar and Fig. 2c top panel), and apparent parenchymal
microcapillary blood volume changes were tracked by monitoring
optical reﬂectance, assumed to vary inversely with parenchymal
blood volume, in a region of interest (Fig. 2b black box and Fig. 2c
bottom). Signiﬁcant increases in macroscopic vessel diameter
(9.5±2.4% dilation, t-test Po10 9, n¼ 5) and decreases in
optical reﬂectance from parenchymal tissue (8.0±2.8% intensity
change, t-test Po10 11, n¼ 5) were observed following wtCGRP
superfusion, demonstrating that CGRP-induced responses can be
sensitively detected by in vivo optical imaging.
We next investigated the ability of wtCGRP to induce contrast
detectable by noninvasive imaging in optically inaccessible
brain regions by acquiring MRI scans during intracranial
infusion of 100 nM wtCGRP in artiﬁcial cerebrospinal ﬂuid
(aCSF) into deep parenchymal tissue. Injections of wtCGRP or
vehicle control at 0.1 ml min 1 were performed through cannulae
bilaterally implanted in arbitrarily selected thalamic regions of
live rat brains, and MRI data were acquired using weighting
parameters suitable for detecting BOLD contrast (Fig. 2d). Voxels
clustered around the sites of wtCGRP injection showed
substantial signal changes that were signiﬁcantly correlated with
a 10min infusion epoch (corrected t-test Po0.05, n¼ 6), whereas
no voxels near control injection sites showed signiﬁcant
correlation. Data from six animals revealed mean peak MRI
signal changes of 5.3±0.9% during wtCGRP injection, compared
with changes of 1.2±0.1% during injection of aCSF alone; the
difference between wtCGRP and vehicle was highly signiﬁcant
(t-test P¼ 0.001). Time courses of mean MRI signal changes
observed during infusion were consistent with the optical imaging
data and indicated that wtCGRP is not rapidly removed or
degraded in brain tissue (Supplementary Fig. 1a). Haemodynamic
contrast provided sufﬁcient resolution to monitor convective
spread of the imaging agent from the site of infusion
(Supplementary Fig. 1b).
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To dissociate wtCGRP-induced image contrast from haemo-
dynamic effects evoked via pathways associated with neural
activity, we performed wtCGRP infusion in the presence or
absence of neuronal nitric oxide synthase (nNOS) inhibition,
which has previously been shown to reduce neural stimulation-
evoked BOLD signals by over 60% (ref. 14). MRI response proﬁles
and amplitudes (Fig. 2e) evoked by wtCGRP, before and after
systemic intravenous injection of the nNOS inhibitor N-nitro-L-
arginine methyl ester (L-NAME; 50mgkg 1) (ref. 15) were
statistically indistinguishable (t-test P40.05). Although L-NAME
injection itself appeared to induce a small average increase in the
baseline brain signal before CGRP infusion (3.5±2.3%), this
change was not statistically signiﬁcant (t-test P¼ 0.11, n¼ 4).
These results demonstrate that wtCGRP can be used to engineer
substantial and speciﬁc image contrast changes in deep brain, at
concentrations about 1,000-fold lower than those at which
conventional MRI contrast agents produce equivalent effects2.
Design of vasoactive protease sensors. To perform molecular
imaging of biochemical targets using CGRP-mediated contrast,
we implemented an analyte-dependent uncaging scheme as
shown in Fig. 1b. We focused on detection of proteases, which are
important as drug targets, diagnostic biomarkers and bases for
biotechnological applications such as cell signalling and prodrug
activation16,17. Since proteases are subject to extensive post-
translational regulation, it is often important to measure their
activity rather than their abundance18, thus necessitating
enzymatically sensitive probes per se.
To rapidly evaluate candidate CGRP-based protease activity
sensors, we developed an in vitro bioassay for CGRP receptor
activation in cultured cells (Supplementary Fig. 2). Cells used for
the bioassay were engineered to co-express the RAMP1/CLR
complex in conjunction with a bioluminescent reporter sensitive
to RAMP1/CLR-mediated cyclic adenosine monophosphate
(cAMP) production, such that effective receptor activation leads
to luminescence signals readily detected in a microtiter plate
reader. Measurements using this system indicated an EC50 for
receptor activation by wtCGRP of 48 pM (95% conﬁdence
interval (CI) 37–63 pM), which was 2.5- to 14-fold impaired by
N-terminal extensions of one to three residues (Supplementary
Fig. 3). C-terminal extension of wtCGRP by addition of a glycine
residue in contrast resulted in a much higher EC50 of 2.5 nM
(CI 2.1–3.1 nM), and substitution of the C-terminal amide of
wtCGRP by a carboxylate reduced potency of the peptide by a
factor ofB250. These ﬁndings are consistent with earlier studies
of terminal modiﬁcations of CGRP19. The relatively modest
effects of N-terminal modiﬁcations to wtCGRP suggested that
protease sensors might best be formed by fusing blocking
domains via protease cleavage sites to the N terminus of CGRP,
so that cleavage products could recover vasodilation activity close
to the wild-type variant.
Guided by these ﬁndings, we designed candidate vasoactive
sensors for a number of proteases relevant to biotechnology
(Fig. 3a). Targets included ﬁbroblast activation protein (FAP),
a cell surface-bound collagenase and cancer biomarker20, which
removes the dipeptide AP from the N terminus of polypeptides;
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Figure 1 | Principle of molecular imaging with CGRP-induced haemodynamic responses. (a) CGRP acts on the heterodimeric G-protein coupled receptor
RAMP1/CLR (left) to induce intracellular cAMP production, resulting in relaxation of vascular smooth muscle cells (VSMCs) and consequent vasodilation
(middle). Dilation of microvasculature induces haemodynamic effects visible by MRI and other imaging methods (right). (b) Design for analyte-sensitive
vasoactive probes comprising CGRP fused to a labile blocking domain via an analyte-responsive linker. Such probes can be activated by analytes that act
sterically on the sensor to unblock the CGRP moiety, for example, by cleaving the blocking domain as shown here. This would induce an analyte-dependent
haemodynamic response and enable molecular imaging with CGRP-based constructs. (c) Application of CGRP as a genetically encoded reporter would
involve expressing prepro-CGRP in genetically modiﬁed cells or tissues. Subsequent processing of the construct should result in secreted CGRP, allowing
the genetically modiﬁed cells to be tracked by haemodynamic imaging methods.
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TEV protease and enterokinase, both well-studied endopeptidases
that are absent in the central nervous system and could, therefore,
be used as bio-orthogonal markers for transgenesis or cell
tracking21,22; and caspase-3 (CASP3), another endopeptidease
and cytosolic apoptosis actuator that can be released following
apoptosis and secondary necrosis23 and serve as a prognostic
indicator during cancer treatments24,25. FAP and CASP3 have
been targeted by previous optical26–28 or MRI29,30 probes, but
improvements in sensitivity for deep tissue detection would be
valuable. CGRP constructs targeted towards these proteases
and incorporating AP repeats, green ﬂuorescent protein (GFP),
or biotin as blocking domains were produced in Escherichia coli
or by solid phase peptide synthesis.
Experimental validation of vasoactive protease sensors.
We then used our in vitro bioassay to identify protease sensor
candidates that displayed minimal activity before cleavage and
high potency after enzyme treatment. We found that uncleaved
recombinant sensors of the format GFP-(cleavable linker)-CGRP-G
were completely inactive as CGRP receptor agonists even at
concentrations of 10mM (Fig. 3b and Supplementary Fig. 4).
After 2 h incubation with their cognate proteases (TEV,
enterokinase or CASP3), the constructs were largely cleaved and
elicited bioluminescence in RAMP1/CLR reporter cells with
apparent EC50 values from B0.4–1.0 mM (Table 1). Amidated
synthetic CGRP-based substrates for FAP and CASP3 regained
much higher levels of potency following cleavage, with EC50
values for FAP of 16 pM (CI 13–20 pM) and for CASP3 of 42 pM
(CI 38–46 pM). These constructs were less effectively inactivated
by blocking domains before cleavage, however, with EC50 values
of 114 pM (CI 112–116 pM) and 5.7 nM (CI 5.2–6.4 nM) for FAP
and CASP3, respectively. Effective conditions for protease sensing
by each of the CGRP constructs could be identiﬁed based on the
shift in EC50 values measured in the bioassay upon cleavage
(Fig. 3c), indicating that each of the candidates could potentially
function as a molecular imaging probe for protease activity
in vivo. Because the optimum protease sensitivity and post-
cleavage potency was displayed by the biotin-(CASP3 site)-CGRP
construct, this variant was selected for validation studies in
animals.
To demonstrate imaging-based detection of the difference
between activated and unactivated CASP3 probes, we again used
the intracranial injection procedure of Fig. 2c. CASP3 sensor
aliquots (100nM) were injected at 0.1mlmin 1 for 10min in the
presence or absence of CASP3 enzyme (2.3 ngml 1) in paired
injections into rat thalamus. MRI scans acquired with BOLD
contrast weighting revealed clusters of voxels for which signiﬁcant
correlation between the injected sensor and the image signal
(corrected t-test Po0.05) was observed in the presence but not the
absence of the co-injected protease (Fig. 3d). The mean MRI peak
signal change observed during sensor/CASP3 co-injection was
7.0±0.9%, whereas the peak signal change observed in the absence
of CASP3 was only 1.6±0.5%; this difference was highly
signiﬁcant, with t-test P¼ 0.02 (n¼ 4). These results demonstrate
that CGRP-based CASP3 sensors elicit engineered haemodynamic
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Figure 2 | Imaging artiﬁcial haemodynamic responses induced by CGRP probes in vivo. (a) Direct effects of superﬁcially perfused CGRP on cerebral
vasculature are assessed by optical reﬂectance imaging of exposed cortex. (b) Cortical image of a single rat, revealing discrete blood vessels (dark) and
parenchymal tissue (light background). Scale bar, 100mm. (c) Time course of average CGRP-induced haemodynamic changes in ﬁve animals; shading
denotes standard errors as a function of time. The CGRP infusion period is denoted by the blue shaded lines. Top panel shows changes in the diameter of
macroscopic vessels as indicated by the red bar in b. Bottom panel shows mean optical signal changes in parenchymal regions as denoted by the black
rectangle in b; downward deﬂection of the curve during CGRP administration is consistent with increasing parenchymal cerebral blood volume, which
darkens images. (d) MRI changes observed in conjunction with deep intracranial injection of CGRP (100 nM) or vehicle only (aCSF), both at 0.1ml min 1.
for 10min into the parenchyma of the thalamus. Coloured voxels overlaid on a greyscale anatomical image (left) indicate the correlation strength of
observed signal changes with the injection period. Bar graph (right) indicates peak signal changes observed upon injection of CGRP or aCSF, each averaged
over corresponding injection regions in multiple animals (black boxes at left, n¼ 6). Scale bar, 5mm. (e) Dissociation of CGRP-induced artiﬁcial
haemodynamic signals from nitric oxide-mediated signalling. Left, haemodynamic responses observed by imaging upon unilateral CGRP injection into the
left thalamus, before L-NAME delivery (-LN, top), or into the right thalamus, after 50mg kg 1 intravenous L-NAME infusion (þ LN, bottom). Sites denoted
by crossed out boxes did not receive CGRP injections under the conditions labelled. Right, comparison of peak percent signal changes observed in regions
as identiﬁed on the left, without and with L-NAME and showing no signiﬁcant difference. Error bars throughout this ﬁgure denote s.e.m. values (n¼4).
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contrast differences appropriate for noninvasive molecular imaging
in deep brain regions. The volumes over which
probe-dependent responses were observed, as well as experience
with conventional MRI contrast agent injections2, suggest that
CGRP variants were diluted approximately tenfold from 100 nM
levels in the infusion cannulae to effective concentrations near
10nM in the brain parenchyma. The magnitude of observed
MRI changes elicited by these probe levels suggests that
substantially lower CGRP concentrations would also be
detectable in the brain.
Construction and demonstration of a vasoactive genetic reporter.
In addition to their utility as building blocks for molecular
sensors, peptidic vasoactive agents like CGRP could function as
reporters of transgene expression. As an initial test of this idea,
we sought to determine whether xenografted cells genetically
modiﬁed to secrete CGRP could be visualized by imaging in rat
brain, as schematized in Fig. 1c. Endogenous CGRP is produced
by proteolytic processing of a prepropeptide and export by
machinery common to mammalian cells. To exploit this
mechanism artiﬁcially, we constructed a bicistronic vector
encoding prepro-CGRP as well as the ﬂuorescent protein mKate
linked to the ampicillin resistance gene Bla via a self-cleaving 2A
peptide (Fig. 4a).
HEK293FT cells were transfected with the prepro-CGRP/
mKate-2A-Bla construct or with a control vector encoding only
mKate-2A-Bla and cultured on selective medium to obtain stable
lines. CGRP production was then assessed by washing the cells
and then performing the RAMP1/CLR activation bioassay of
Supplementary Fig. 2 on aliquots of growth medium withdrawn
at deﬁned time intervals following the wash. Results were
compared with a standard curve obtained with known amounts
of synthetic CGRP and demonstrated that cells expressing
prepro-CGRP release an average of between 10 19 and 10 18
mol CGRP per cell over a 24 h period. Given the detection limit
for CGRP below 10 nM by MRI in rat brain, we, therefore,
predicted that cell densities between 104 and 105 cells per ml
should be easily detectable over analogous time periods in vivo.
This is competitive with existing genetic MRI reporters for cell
tracing21 and could be further optimized if desired.
To assess the ability of CGRP-expression constructs to
induce detectable vascular contrast in vivo, cells expressing the
prepro-CGRP/mKate-2A-Bla vector or the control vector were
injected intracranially into rat striatum and imaged by MRI at
time points immediately before and 1 day after implantation.
Signal brightening consistent with vasodilation in the neighbour-
hood of the CGRP cell injection, but not the control injection, was
discernable by simple visual inspection of T2-weighted MRI scans
obtained at the 24 h time point (Fig. 4b). Quantitative analysis of
the signal change observed between day 0 and day 1 (Fig. 4c)
revealed an average of 23±3% signal change induced in the
region of CGRP-expressing cells and an average of 7±2% signal
change induced near control cells; this difference was highly
signiﬁcant (t-test P¼ 0.01, n¼ 5), demonstrated speciﬁc detection
of the CGRP expression construct. The larger magnitude of
observed signal change, compared with effects of acute CGRP
injection (Fig. 2c), may reﬂect a greater extent of affected tissue.
Importantly, the region of MRI signal enhancement observed in
individual animals corresponded closely to the distribution of
transplanted prepro-CGRP-expressing cells, as indicated by
post-mortem histological analysis of mKate ﬂuorescence after
MRI procedures (Fig. 4d). Injected control cells displayed robust
mKate expression in the absence of MRI enhancements,
and neither test nor control injections resulted in gross tissue
disruption or evidence of toxicity (Supplementary Fig. 5). These
results, therefore, conﬁrm the utility of CGRP as a genetic tool for
cell monitoring in the brain. Importantly, applications can be
envisioned which combine genetic control of vasoactive agents
with analyte-switchable behaviour to probe both internal cell state
and the extracellular biochemical context of genetically speciﬁed
cell populations, a key problem in the ﬁeld31.
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Figure 3 | Design and assessment of protease-activated imaging probes
based on CGRP. (a) Protease sensor designs incorporate an N-terminal
blocking moiety (green), a protease cleavage sequence (red, cleavage sites
indicated by triangles), and a C-terminal CGRP moiety (blue). Structures of
ﬁve protease sensors are shown, with cognate proteases labelled in red
text: (1) The synthetic peptide AP-CGRP-amide detects dipeptidase activity
of ﬁbroblast activation protein (FAP). (2–4) Recombinant fusion proteins
comprises cysteine-free GFP, a short linker, a protease site and
non-amidated CGRP detect TEV protease (2), enterokinase (EK) (3) and
caspase-3 (CASP3) (4). (5) The synthetic peptide (long-chain biotin)-SG-
DEVD-CGRP-amide also detects CASP3 activity. (b) Dose–response curve
for sensor (5) measured using a cell-based bioassay32 (Supplementary
Fig. 2) following incubation with or without CASP3. Luminescence
values were normalized, and error bars reﬂect s.d. from n¼ 3 replicates.
(c) Protease sensing by CGRP-based probes measured in vitro, using probe
concentrations indicated. Error bars represent s.d. of n¼ 3 replicates.
Sensors were incubated with or without corresponding proteases: (1) with
5 ngml 1 of human FAP; (2) with 0.1 Uml 1 of TEV protease; (3) with
2 pgml 1 of EK light chain; (4) with 23 ng ul 1 and (5) with 11.5 ng ml 1 of
human CASP3. (d) Left, protease-dependent switching of 100nM
CGRP-based molecular imaging probe (5) induces contrast differences in
MRI. Signiﬁcant haemodynamic activation can be seen in the presence but
not the absence of coadministered 1.15 ng ml 1 CASP3. Right, bar graph
showing peak signal change induced by uncleaved versus cleaved sensor
(5). Error bars throughout this ﬁgure indicate s.e.m. values over n¼4
animals.
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Discussion
Our data show that engineered haemodynamic signals can provide
a sensitive, highly versatile, and conceptually unprecedented
alternative to established molecular imaging approaches. By
exploiting changes in an endogenous physiological property, this
strategy avoids the need for directly detected imaging agents.
Concentrations of vasoactive molecules necessary for imaging
approach the low tracer doses used in nuclear medicine techniques
like ﬂuorodeoxyglucose PET32, and unlike radiotracers, CGRP
derivatives are activatable by molecular targets, genetically
encodable, intrinsically less hazardous, detectable at higher
spatiotemporal resolution, and compatible with multiple
diagnostic modalities. Utility of the new probe technology for
genetic reporting in the brain is directly demonstrated by our
methods, and can enable tracking of genetically labelled
transplanted cells, monitoring of gene therapy or detection of
genetic program activation in engineered cells and tissues.
Vasoactive protease sensors introduced here only constitute a
proof-of-concept for analyte-dependent molecular imaging, but
could be adapted and applied in future work for measurement of a
large variety of biological targets of interest.
Further work can improve in a number of ways on the new
technology introduced here. Improvements in probe delivery are
especially critical. Application of vasoactive probes beyond the
brain should beneﬁt from widespread activity of CGRP in
multiple tissues33, but has yet to be demonstrated. For future
non-genetic applications, development of a strategy that
promotes efﬁcient extravasation of intravenously injected
CGRP-based probes might be critical for molecular imaging
in some tissues. In the brain, noninvasive delivery past the
blood–brain barrier (BBB) will be a particular priority, especially
to address the challenge of translating this method into human
subjects. Fortunately, the minimal amounts of vasoactive probes
required for engineered haemodynamic imaging are likely to be
conducive in the future to noninvasive trans-BBB delivery by
means of receptor-mediated transcytosis, a delivery technique
which is proving successful in rodents, non-human primates and
human clinical trials34. A variety of alternative vector-based or
BBB disruption-dependent strategies might also enable effective
brain delivery35, particularly given the low concentrations
required for molecular imaging with vasoactive agents.
Table 1 | Effect of cleavage on the potency of CGRP-based
protease sensors.
Construct Log(EC50)
Uncleaved Cleaved
CGRP-NH2 NA  10.3
CGRP-G NA 8.6
Sensor (1)  9.9  10.8
Sensor (2) o 5 6.0
Sensor (3) o 5 6.4
Sensor (4) o 5 6.4
Sensor (5)  8.2  10.4
NA, not applicable.
Log(EC50) values obtained by dose–response curve measurement from sensors (1–5) from Fig. 3
incubated with or without corresponding proteases: (1) with 5 ngml 1 of human FAP; (2) with
0.1 U ml 1 of TEV protease; (3) with 2 pgml 1 of enterokinase light chain; (4) with 23 ng ul 1
and (5) with 11.5 ng ml 1 of human CASP3. s.e.m. values were all o0.1 (n¼ 7).
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Figure 4 | Application of CGRP as a genetically expressed vasoactive reporter. (a) Lentiviral vectors were used for expression of prepro-CGRP or a
control construct. Top: probe vector controlled by the hEF1a promoter, encoding human prepro-CGRP (prepro-hCGRPa), an internal ribosome entry site
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activation by aliquots of puriﬁed CGRP peptide (light blue) or supernatants from cultured cells expressing control (grey) and prepro-CGRP (dark blue)
lentiviral constructs was measured using the bioassay of Supplementary Fig. 2. Cell supernatants were assayed at 0 and 24 h after an initial washing, and all
samples were assayed at tenfold dilution. Error bars denote s.d. of n¼ 3 replicates. (c) In vivo detection of implanted HEK293FTcells producing CGRP in rat
brains. A representative T2-weighted MRI scan obtained 24 h after striatal injection of 3 105 CGRP-producing or control cells (labels above) shows
discernable signal enhancement consistent with probe-induced vasodilation in the CGRP injection region (dashed box) but not near the control injection
site opposite. (d) Left: group-averaged map (left) displaying percent signal change (%SC, colour scale) observed between 0 and 24 h after cell
implantation, averaged over ﬁve animals. Right: mean %SC in the square regions of interest superimposed on the image. Error bars denote s.e.m. across ﬁve
animals. (e) Correspondence of MRI signal change (left, colour scale as in d) measured in vivo and mKate expression (right, red superimposed over a bright
ﬁeld image) visualized postmortem in a representative animal. The ﬁeld of view corresponds to the rectangular box in c. Scale bar, 2mm.
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Additional limitations of vasoactive probe technology must
also be addressed in future research. One problem is the semi-
quantitative nature of molecular imaging with vasoactive probes,
compared with approaches based on more conventional imaging
agents. This limitation arises from the nonlinear relationships
among vasoactive probe concentration, haemodynamic para-
meters, and contrast patterns produced in images36. Although
quantiﬁcation of probe responses might not be required for
detecting the mere presence versus absence of analytes or probe-
expressing cells, more quantitative readouts would be needed for
absolute measurements of continuously varying molecular or
cellular parameters, such as analyte concentrations, or for
comparison of such variables across different subjects or
treatments. In these cases, approximately quantitative responses
would have to be inferred from in vitro probe measurements
(EC50 values and receptor afﬁnities), in combination with
haemodynamic modelling37,38 and calibration techniques39,40.
In animals, it might also be possible to quantify vasoactive probe
readouts with respect to standard curves obtained by injecting
known concentrations of probes and analytes. A possible
confound to either qualitative or quantitative vasoactive probe
measurements could arise in situations where cerebral vasculature
is perturbed by injury or pathology. Conditions such as ischemia41
and haemorrhage42 are likely to affect vascular contrast at least in
MRI, and may also compromise vascular reactivity required for
visualizing vasoactive probes. A further potential complication with
the use of CGRP-based probes in particular might arise from the
role of CGRP signalling in migraine43,44. This problem could be
circumvented using vasoactive alternatives to CGRP, such as
molecular interventions in nitric oxide, cyclooxygenase, and
norepinephrine-mediated vasodilation and vasoconstriction
pathways45. In each case, however, physiological side effects of
candidate probes would need to be investigated and mitigated or
controlled for where appropriate.
In addition to the possibility of performing molecular imaging
using various different engineered haemodynamic response
mechanisms, it might be possible to create diagnostic outputs
by exploiting physiological processes unrelated to blood ﬂow.
Examples might include biological systems related to
endothermia, secretion, or autonomic responses, for instance.
In each case, manipulation of endogenous image contrast of
physiological origin could beneﬁt from endogenous signalling
pathways and ampliﬁcation mechanisms, while avoiding the
adverse consequences of many exogenous diagnostic agents.
Molecular imaging with engineered physiology, therefore,
represents a versatile paradigm for biological experimentation
and diagnostic medicine, as well as a basis for extension of
‘synthetic biology’ concepts to organismic scale.
Methods
Animal procedures. All animal procedures were conducted in accordance with
National Institutes of Health guidelines and with the approval of the MIT
Committee on Animal Care. Sample sizes were estimated based on the effect size
observed in previously published studies to achieve power of 0.8 and alpha¼ 0.05
using Biomath software (http://biomath.info/power/). All experiments were
performed with male Sprague-Dawley rats, age 10–12 weeks, supplied by Charles
River Laboratories (Wilmington, MA).
Optical imaging of exposed cortex. Optical imaging experiments were
performed using Sprague-Dawley rats (300–400 g; Charles River, Wilmington,
MA). To probe the impact of wild-type a-isoform calcitonin gene related peptide
(wtCGRP) on vascular diameter and parenchymal blood volume in vivo, we
measured the effects of topical application to the primary somatosensory cortex
(SI) of rats. Animals (n¼ 5) were initially anaesthetized with isoﬂurane (3% in
50:50 air:O2 mixture for induction; 1% for maintenance). Breathing rate and
end-tidal expired isoﬂurane (V9004 Capnograph Series, Surgivet, Waukesha, WI)
were continuously monitored during the imaging experiment. The animals were
positioned on the surgical stereotax and the isoﬂurane anaesthesia was maintained
at 1% during imaging. During the surgical and imaging procedures, animals were
maintained at B37 C core temperature using a heating blanket.
The preparation for optical imaging is diagrammed in Fig. 2a. A craniotomy
(diameter of B5mm in rats) and durotomy were performed over primary
somatosensory cortex (SI) of each animal, and the cortex was protected with
Kwik-Cast silicone elastomer sealant (WPI, Sarasota, FL, USA). An imaging chamber
was then attached with dental cement and the elastomer was removed. The imaging
chamber was custom made using a 1 cm diameter plastic ring (McMaster-Carr,
Elmhurst, IL, USA) with a base cut to match the skull topography over each rat’s SI
region. To facilitate wtCGRP perfusion at a constant rate, holes for ﬂuid inlet, outlet
and pressure regulation were drilled in the wall of this chamber, through which
blunted 18-gauge stainless steel needles were attached and sealed using superglue. The
pressure in the imaging chamber was regulated by a small vertical tube whose height
could be adjusted. Inﬂow and outﬂow were controlled using two separate syringe
pumps (Harvard Apparatus, Holliston, MA, USA) that were operated at the same rate
(1.8ml per h). The volume of the imaging chamber was B0.3ml, and this chamber
was ﬁlled with artiﬁcial cerebral spinal ﬂuid (aCSF; Harvard Apparatus, Holliston,
MA, USA) and sealed with a cover glass.
A charge-coupled device camera (Prosilica GC, Allied Vision, Newburyport,
MA) attached to a dissection microscope (Stemi SV11 M2 Bio, Carl Zeiss AG,
Oberkochen, Germany) was used to image the cortical surface at a frame rate of
B4Hz. Illumination was regulated using a xenon arc lamp. A green band-pass
ﬁlter (550 þ / 25 nm) was used to provide optimal vascular contrast. A 50 nM
wtCGRP (human a-CGRP, Sigma-Aldrich, St Louis, MO, USA) solution was
prepared in aCSF for each imaging experiment. To establish imaging baselines,
aCSF alone was continuously infused (1.8ml per h) through the inlet port for 5min
before wtCGRP infusion; images were acquired continuously throughout. Fluid was
extracted from the imaging chamber through the outlet port at an equal rate, in
order to maintain a constant pressure. A microﬂuidic switch designed to minimize
propulsion impact and delay with 12 ml dead space was used at the end of the
baseline period to switch the infusion from aCSF to 50 nM wtCGRP in aCSF
solution. A volume of 0.3ml total of this material was perfused at the rate of 1.8ml
per hour. Impact of wtCGRP on the diameter of a cerebral artery (red bar, Fig. 2b)
and on parenchymal blood volume (black rectangle, Fig. 2b) was quantiﬁed using
ImageJ46. Image signal intensity in a region without discernable blood vessels was
used as an indicator of parenchymal volume changes. Statistical analysis of all
measurements was performed in Matlab (Mathworks, Natick, MA, USA).
Magnetic resonance imaging. Nineteen Sprague-Dawley rats were used for
in vivo MRI experiments. Before MRI experiments, rats underwent surgery under
isoﬂurane anaesthesia, and bilateral cannula guides (22 gauge, Plastics One,
Roanoke, VA) were implanted over the ventral posterolateral nucleus of the
thalamus (VPL; 3mm lateral to midline, 4mm posterior to bregma and a depth
of 5mm from the cortical surface) for data shown in Figs 2 and 3, or the caudate-
putamen region of the striatum (CPu; 3mm lateral to midline, 0.5mm anterior to
bregma and a depth of 5mm from the cortical surface) for the data shown in Fig. 4.
A head post was also attached atop their skulls using dental cement (C&B
Metabond, Parkell, Inc., Edgewood, NY, USA), during this surgery. Cannula guides
were sealed with dummy cannulae to avoid exposure of brain tissue during the
recovery period. Further experiments were performed after three or more days of
post-operative care. Immediately before each experiment, two injection cannulae
(28 gauge, Plastics One, Roanoke, VA, USA) were attached to 25 ml Hamilton glass
syringes and preﬁlled with the appropriate intracranial injection solution (aCSF,
wtCGRP, cleaved or uncleaved CGRP-based sensors, CGRP-expressing or control
HEK293FT cells). Injection cannulae were then lowered into the previously
implanted bilateral cannula guides. The Hamilton syringes were then placed in a
remote infuse/withdraw dual syringe pump (PHD 22/2,000; Harvard Apparatus,
Holliston, MA, USA).
Animals were scanned by MRI to measure the changes in haemodynamic
contrast following intracranial injections. Data were acquired on a 7T 20 cm inner
diameter, horizontal bore magnet (Bruker BioSpin MRI GmbH, Ettlingen,
Germany). Home-built and commercial (Insight Neuroimaging Systems, Worcester,
MA, USA & Doty Scientiﬁc, Columbia, SC) radiofrequency coils designed for rat
brain imaging were used for excitation and detection. During imaging experiments,
animals were anaesthetized with isoﬂurane (3% in oxygen for induction; 1% for
maintenance). Breathing rate and end-tidal expired isoﬂurane were continuously
monitored. Anaesthetized animals were attached via their head posts to a head
holder designed to ﬁt within the radiofrequency coil systems. Animals with their
radiofrequency coils were inserted into the magnet bore and locked in a position
such that the head of the animal was at the centre of the magnet bore.
MRI assessment of injected CGRP probes and sensors. High resolution
T2-weighted anatomical scans of each animal were obtained using a rapid
acquisition with relaxation enhancement (RARE) pulse sequence with echo
time (TE)¼ 44ms, recycle time (TR)¼ 2,500ms, RARE factor¼ 8, spatial
resolution¼ 100 100 500 mm, and matrix size¼ 128 128 with seven slices.
Haemodynamic contrast image series were acquired using a gradient echo echo
planar imaging (EPI) pulse sequence with TE¼ 34ms, TR¼ 4,000ms, spatial
resolution¼ 300 300 500 mm, and matrix size¼ 64 64 with seven slices.
To parallel the optical imaging experiments, 5min of baseline measurement with
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4 s per image were acquired before probe infusion. Following this baseline period,
while continuously collecting EPI scans, infusion pumps were remotely turned on
to commence intracranial injection (in the parenchymal tissue) of 1 ml aliquots of
CGRP or control solutions at the rate of 0.1 ml min 1 through the cannulae. For
the experiments of Fig. 2d, aCSF (control) and 100 nM wtCGRP in aCSF were
injected simultaneously through the bilaterally implanted cannulas. For the
experiments of Fig. 3d, CGRP-based CASP3 sensors (100 nM) were co-injected
simultaneously, either with or without comixed CASP3 enzyme (1.15 ng ml 1). For
the nNOS inhibition experiment of Fig. 2e, a bilateral simultaneous injection of
wtCGRP and aCSF was performed as in Fig. 2d. Then 50mg kg 1 of the nNOS
inhibitor N-nitro-L-arginine methyl ester (L-NAME, Sigma-Aldrich, St Louis, MO,
USA) was injected via the tail vein. Fifteen minutes after L-NAME injection,
wtCGRP and aCSF injection lines were switched, and intracranially injected to
assess the effect of CGRP on haemodynamic contrast in the presence of nNOS
inhibition.
MRI data was processed and analysed using the AFNI software package47. The
AFNI 3dAllineate command was used to align each animal’s EPI data set to the
corresponding RARE anatomical image. Each animal’s image data were then
aligned to a reference MRI rat atlas48. To identify voxels with signiﬁcant increases
or decreases in BOLD signal, we used the 3dDeconvolve routines in AFNI to
correlate individual or group level voxel-level signal changes with the injection
epochs. For correlation analysis, injection epochs were modeled by ‘box car’
regressors with a single stimulus block synchronized with the onset and offset of
infusion, without delays. Activation in a region was deemed signiﬁcant if a cluster
of at least four contiguous voxels displayed a raw P-valueo0.001 for positive or
negative correlation between the voxel time courses and the regressors. No
signiﬁcant negative correlation was observed. The cluster size and P value threshold
were objectively chosen, based on AFNI’s AlphaSim routine, to provide a type I
error rate of 5% after correction for multiple comparisons49,50; this was appropriate
for robust hypothesis testing on individual voxels throughout the entire imaging
volume. For visualization, group statistical maps were overlaid on a reference
anatomical image as in Fig. 2d. Time courses were obtained by averaging MRI
signal over 1.5 1.5mm regions of interest deﬁned around cannula tip locations in
individual animals’ data sets. The peak percent signal change was determined by
comparing signal values during baseline and infusion conditions. Additional
statistical analysis was performed in Matlab.
MRI of implanted cells. High resolution T2-weighted anatomical scans of each of
animal (n¼ 5) were obtained using a RARE pulse sequence with TE¼ 44ms,
TR¼ 2,500ms, RARE factor¼ 8, spatial resolution¼ 100 100 1,000 mm and
matrix size¼ 128 128 with seven slices before injecting HEK293FT cells (day 0).
After an initial scan, 3 ml of the cell suspension solution (B100,000 cells per ml) was
intracranially injected in CPu (CGRP-expressing cells in left hemisphere and
control cells in the right hemisphere) at the rate of 0.1 ml min 1. Animals were
taken out from the scanner, recovered form anaesthesia, and returned to their
home cages.
Animals were reimaged 24 h after the cell injection (day 1) using the same scan
parameters as applied before the cell injection. To quantify the signal change in the
T2-weighted MRI images, day 0 and day 1 data sets were registered with each other
using the 3dAllineate routine in AFNI. For visualization, maps of percent signal
change on day 1 compared with day 0 were then arithmetically computed and a
map of average changes was overlaid in colour over a greyscale anatomical image.
Thresholds for display were chosen based on signal changes observed outside the
regions of cell injection. Quantiﬁcation of the percent signal change on day 1
compared with day 0 was performed within 1.5 1.5mm square regions of interest
(white squares in Fig. 4d) deﬁned around the sites of CGRP or control cell injection.
Histology. After MRI cell tracking experiments, animals were transcardially
perfused with phosphate buffered saline followed by 4% formaldehyde in
phosphate buffered saline. Brains were extracted, post-ﬁxed overnight at 4 C, and
then cryoprotected in 30% sucrose for 24–48 h before sectioning. Free-ﬂoating
sections (50mm) were cut using a vibratome (Leica VT1200 S, Leica Microsystems
Gmbh, Wetzlar, Germany), mounted on glass slides with Vectashield mounting
medium with 4,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame,
CA, USA) and protected with a coverslip. The distribution of injected HEK293FT
cells was indicated by red ﬂuorescence due to mKate2 reporter expression in both
CGRP-producing and control cells.
Plasmids. A tabulated list and sequences for all plasmids used in this study are
provided as Supplementary Tables 1–8. Lentiviral helper plasmids pMD2.G
(Addgene #12259, Cambridge, MA) and psPAX2 (Addgene #12260) were gifts
from Didier Trono. Plasmids pEF-ENTR A (Addgene #17427) and pLenti X1 Zeo
(Addgene #17299) were gifts from Eric Campeau51. Bacterial expression plasmids
Z503, Z507 and Z508 were cloned using the Golden Gate method52 by assembling
synthetic DNA sequences (IDT, Coralville, IA, USA) and PCR amplicons into the
backbone of pEF-ENTR A. cfSGFP2 is a cysteine-free variant of the GFP53. CGRP
is the alpha-isoform of human CGRP. Lentiviral plasmids were cloned using the
Golden Gate method by assembling fragments for the polycistronic expression
cassettes into a variant of the pLentiX1 Zeo plasmid with its kanamycin resistance
replaced by the ampicillin resistance cassette from pUC18. Each lentiviral plasmid
used in this study contains a gene of interest followed by an internal ribosome
entry site and a selection marker comprising a ﬂuorescent protein, a 2A viral
sequence54, and an antibiotic resistance gene. The HA-tagged human CLR and
myc-tagged human RAMP1 sequences, together encoding the two components of
human CGRP receptor, were previously functionally characterized55. The Glo22F
gene encodes an engineered luciferase whose activity is modulated by cyclic AMP
(Promega, Madison, WI, USA)56.
Plasmids were assembled by one-pot restriction and ligation using an optimized
Golden Gate protocol. DNA fragments were obtained as double-stranded synthetic
DNA gBlocks (IDT), annealed oligonucleotides (IDT), or PCR products and either
used directly or subcloned into a backbone with different antibiotic resistance.
For each fragment, 40 fmol were added to a reaction containing 0.7 ml highly
concentrated (HC) T4 ligase (Promega), 1 ligase buffer, 0.3 ml BsaI and
1 bovine serum albumin (New England Biolabs, Ipswich, MA, USA) in a ﬁnal
volume of 10ml. The reaction was performed in a thermocycler using the following
program: 1 (37C, 5min); 25 (37C, 2min; 16C; 5min); 1 (50C, 5min; 80C,
5min); hold at 4C. The reaction product (2 ul) was transformed into chemically
competent E. coli (E. cloni 10G, Lucigen Corp.). DNA preparations from
kanamycin-resistant clones were screened by restriction digest and veriﬁed by
sequencing (Genewiz).
Lentiviral plasmids C504, C505 and C512 were cloned as above, veriﬁed and
then re-transformed into Stbl3 cells (New England Biolabs) for plasmid
production. Liquid cultures were grown in 50ml LB and DNA was extracted by
midi-prep (Qiagen, Valencia, VA, USA).
Mammalian cell culture. HEK293FT cells were purchased from Life Technologies
(Grand Island, NY) and cultured in 90% DMEM medium, supplemented with
2mM glutamine, 10% fetal bovine serum (FBS), 100 units per ml penicillin, and
100 mgml 1 streptomycin. Cells were frozen in freezing medium composed of 50%
unsupplemented DMEM, 40% FBS and 10% dimethylsulfoxide. The cells tested
negative for mycoplasma contamination in the MycoAlert assay (Lonza, Walk-
ersville, MD, USA). This cell line was chosen because of its extensive prior use and
validation for lentivirus production51, for CGRP receptor activity assays55, and for
brain implantation57. We performed no further authentication of the identity of the
HEK293FT cell line because we obtained it from a trusted source and because
functional validation of lentiviral gene transfer, of CGRP reporter performance,
and of CGRP secretion as described in the main text was satisfactory.
Lentivirus production. HEK293FT cells were seeded into 6-well plates at 1 million
cells per well and transfected using Lipofectamine 2000 (Life Technologies, Grand
Island, NY) according to instructions at sub-conﬂuence. Co-transfection of 0.5 mg
pMD2.G, 1 mg psPAX2 and 1 mg of the lentiviral plasmid of interest was performed
with 6.25 ml Lipofectamine 2000 reagent. Virus-containing supernatant was
collected after 48 and 72 h, ﬁltered through 0.45 mm ﬁlters, and used for infection
without further concentration. Supernatants were stored at 4 C for up to a week.
Lentiviral infection and cell line generation. HEK293FT cells were seeded into
24-well plates at 40,000 cells per well (ﬁnal) in the presence of 4 mgml 1 Polybrene
in 50% fresh medium and 50% viral supernatants containing between one and
three different viruses. The medium was replaced with fresh viral supernatants
daily for 2 days (infection with single virus) or 4 days (triple infection). Selection
was performed using both antibiotic resistance and ﬂuorescent markers for each
lentivirus. Beginning on day 3 after initial infection, appropriate antibiotics
(blasticidin at 10mgml 1, puromycin at 1 mgml 1, hygromycin at 250 mgml 1,
or combinations; all from Life Technologies) were added to the medium for
selection and selection was continued until all cells expressed the appropriate
ﬂuorescent markers. Selection was then discontinued, cells were expanded and
aliquots were frozen down.
Luminescent cAMP assay for CGRP receptor activation. The GloSensor cAMP
assay56 (Promega) was used to measure cAMP generation upon CGRP receptor
activation in real time. HEK293FT reporter cells were virally transduced with an
engineered luciferase whose activity is subject to fast allosteric modulation by
cytosolic cAMP. We generated one HEK293FT cell line carrying only the lentiviral
construct encoding the engineered luciferase (negative control) and another cell
line carrying three lentiviral expression constructs, encoding the engineered
luciferase and the two components of the heterodimeric CGRP receptor (CGRP
reporter cell line); see Supplementary Fig. 2.
On day 0, 10,000 cells per well were seeded in 100 ml DMEMþ 10% FBS in
white opaque clear-bottom 96-well plates (Costar #3610, Coppell, TX). On day 1 or
2, the medium was removed from the wells and replaced with 90 ml per well
of Gibco CO2-independent medium (Life Technologies)þ 10% FBS containing
1% v/v of cAMP GloSensor substrate stock solution (Promega). The cells were
incubated in substrate-containing medium at 37 C in 5% CO2 for at least 2 h
(maximally 8 h). Before the luminescence bioassay, cells were removed from the
cell culture incubator and equilibrated to room temperature and atmospheric CO2
for 30min. Then, a pre-addition read was performed for 10min to establish a
baseline for luminescence. Compounds and reaction products to be tested were
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quickly added in 10 ml volume per well at 10 of the desired ﬁnal concentration
using a multichannel pipette. A 30min time resolved readout of luminescence was
then performed post-addition with time points every 60 or 90 s, and the time
course was examined to conﬁrm a plateau in the signal after 10–15min, persisting
at least through the 25min time point. All further data analysis was performed on
the basis of the luminescence intensity at the 15min post-addition time point.
Bioassay data analysis. Data analysis was performed with a custom Python
program. Unless stated otherwise, luminescence intensities at minute 15 were
normalized within each microplate to 0.0¼ blank signal from reporter cells
with buffer added and 1.0¼ signal from reporter cells with 100 nM of wild-type
synthetic human alpha CGRP (Sigma) added. Triplicate wells were grouped and
the mean and standard deviation for each compound concentration were plotted
and used for weighted least squares regression. Dose–response curves were ﬁt to a
four-parameter Hill equation of the following form:
y ¼ aþ b að Þx
n
xnþ 10kð Þn ð1Þ
x is the concentration of CGRP or equivalent, y is the luminescence reading, a and
b are baseline constants, k is the logarithm of the EC50 value, and n is the effective
Hill coefﬁcient. Fitting was performed by weighted nonlinear least-squares
regression with the Levenberg-Marquardt algorithm as implemented in the leastsq
module from the Scientiﬁc Python library. For dose–response curves that did not
reach a plateau over the examined concentration range, the values of the
asymptotes were constrained to a¼mean value of blank and b¼mean value of
100 nM wtCGRP and only n and EC50 were allowed to vary. For curves that never
left the baseline (maximum activityo10% of activity of 100 nM wtCGRP), no
attempt was made to determine an exact value of EC50. Standard errors for
log(EC50) values were computed using the delta method and converted to
asymptotic 95% CI (CI values noted in the text) for EC50 and log(EC50).
Reporter validation. Forskolin, wtCGRP, and [8–37]CGRP were purchased from
Sigma-Aldrich and used in bioassays as described above. To determine whether
CGRP responses were speciﬁcally mediated by RAMP1/CLR, two HEK293FT cell
lines were used, one expressing the Glo22F cAMP-responsive luciferase only and
the other also expressing the RAMP1/CLR CGRP receptor heterodimer. All
luminescence values were normalized from zero to one using baseline values
obtained from buffer only or addition of 100 mM forskolin on the same respective
cell line. In a separate experiment, CGRP dose–response curves were obtained in
the presence of [8–37]CGRP on reporter cells expressing RAMP1 and CLR.
[8–37]CGRP is an N-terminally truncated CGRP variant that acts as a competitive
inhibitor of CGRP agonist activity and is expected to shift CGRP dose–response
curves to the right. Here luminescence data were normalized between values
obtained for buffer only and 100 nM CGRP only.
Peptide synthesis. CGRP-like peptides were made by solid-state synthesis
at the MIT Koch Institute Biopolymers lab, oxidatively cyclized and puriﬁed by
high-performance liquid chromatography. Identity and purity were conﬁrmed by
matrix-assisted laser desorption ionization-time of ﬂight (MALDI-TOF) mass
spectrometry and analytical high-performance liquid chromatography. After
lyophilization, the peptides were weighed, dissolved in water or 50%
dimethylsulfoxide, and quantiﬁed rigorously using a ﬂuorescent microplate assay
(FluoroProﬁle, Sigma-Aldrich) with CGRP from Sigma-Aldrich as a concentration
standard. The peptide solutions were then adjusted to a stock concentration of
100mM and stored at  20 C.
Production and puriﬁcation of GFP-CGRP fusions. GFP-CGRP fusions
were expressed from a T7 promoter upon induction with 0.4mM isopropyl
b-D-1-thiogalactopyranoside in E. coli BL21 cells (New England Biolabs). Cells
were grown in 50ml LB medium at 37 C to an optical density at 600 nm of
0.4–0.6, induced, and expression was allowed to proceed for 3–5 h at 37 C. Cell
pellets were collected, lysed with BugBuster (EMD Millipore, Billerica, MA), and
processed for inclusion body preparation according to the manufacturer’s
instructions. Inclusion bodies were dissolved in 5ml denaturation buffer (6M
guanidinium HCl, 20mM dithiothreitol, 50mM Tris-HCl, pH 7.5) overnight and
the absorbance at 280 nm (A280) was measured. Extinction coefﬁcients at 280 nm
(e280) and molar masses (MWs) were computationally predicted from the amino-
acid sequence [sensor (2): e280¼ 26,980 cm 1 M 1, MW¼ 33,174Da; sensor (3):
e280¼ 25,700 cm 1 M 1, MW¼ 32,911Da; sensor (4): e280¼ 25,700 cm 1 M 1,
MW¼ 32,780Da]. From these values and the measured 280 nm absorbances,
concentrations were then calculated and adjusted to 0.5mgml 1 for refolding.
Refolding was performed by dialysis of 40ml denatured protein solution against
refolding buffer (100mM NaCl, 20mM Tris-HCl, pH 7.5). Insoluble material was
removed from the refolded solution by centrifugation (16,000g for 20min) and the
supernatant containing soluble protein was concentrated to a volume of 3–4ml.
The fusion protein was isolated by StrepII afﬁnity puriﬁcation using 1ml
StrepTactin agarose resin (Qiagen) with refolding buffer as wash buffer. Elution
buffer additionally contained 2.5mM desthiobiotin. Fractions containing the bulk
of eluted protein (as judged by green colour) were pooled, buffer exchanged
into storage buffer (identical to refolding buffer) using NAP-10 size exclusion
columns (GE Healthcare), and concentrated with spin columns. A280 values were
determined and concentrations of the stock solutions were adjusted to 100 mM
using predicted extinction coefﬁcients and MWs. Purity and identity of the proteins
were veriﬁed by sodium dodecylsulfate–polyacrylamide gel electrophoresis and
MALDI-TOF mass spectrometry. Stock solutions were stored for up to 2 weeks at 4 C.
Proteolytic cleavage reactions. Recombinant human FAP alpha expressed in
Sf21 cells (400–600 ng ml 1; Sigma-Aldrich product F7182), recombinant human
CASP3 expressed in E. coli (230 ng ml 1; Sigma-Aldrich product C1224), ProTEV
Plus protease (5U ml 1; Promega product V6101) and enterokinase light chain
(2 ng ml 1; New England Biolabs product P8070) were purchased from commer-
cial sources and used at the ﬁnal concentrations indicated for each experiment.
Reactions were performed by combining varying concentrations of the relevant
protease and the desired concentration of the sensor peptide or fusion protein
(10 the highest desired ﬁnal concentration in the bioassay) in reaction buffer
(100mM NaCl, 20mM Tris-HCl, pH 7.5), and incubating the mixture at 37 C for
2 h. These conditions permitted all investigated proteases to achieve near-complete
cleavage, as indicated by our assays. For cleavage reactions followed by serial
dilution and CGRP bioassays, 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) was included in the reaction buffer to reduce
adsorptive loss of free peptides. For cleavage mixtures used for in vivo injection,
CHAPS was omitted. The extent of cleavage was assessed in each case by
SDS–polyacrylamide gel electrophoresis for fusion proteins and by MALDI-TOF
mass spectrometry for small peptide substrates.
In vitro bioassay for CGRP secretion. Gelatin-coated 6-well tissue culture plates
were seeded with 106 HEK293FT cells per well carrying a lentiviral transgene
(either C503 prepro-CGRP or C501 control) on day 1. On day 2, each well was
covered byB2 106 conﬂuent, contact-inhibited cells. The medium was aspirated,
the cell layers were washed twice with fresh medium, and 2ml fresh medium were
added. Aliquots of the culture supernatant (100 ml) were taken immediately and
again after 24 h (on day 3). To quantify the CGRP-like bioactivity in the culture
supernatants, 10ml of each sample was added to bioassay wells containing 90 ml
CO2-independent medium, in triplicate. As a positive control and reference
standard, known dilutions of synthetic wtCGRP (Sigma) were prepared in culture
mediumþ 0.1 % CHAPS and added at the same 1:10 dilution. Culture medium
alone served as the buffer-only control.
CGRP secretion (in mol per cell per day) was calculated from the CGRP
bioactivity in the culture supernatant (in nM) by assuming 2 106 in 2ml
medium, or 109 cells l 1 and, therefore, multiplying the measured concentration
by 109 (nM/M) 109 (cells l 1). The required concentration of cells (in cells ml 1)
for in vivo detection was calculated by assuming a need for 10 nM CGRP
(10 8 mol l 1¼ 10 14 mol ml 1) per day by the quantity of secreted CGRP
(in mol per day) per cell.
Preparation of cells for in vivo implantation. HEK293FT cells carrying a C503
prepro-CGRP or a C501 control lentiviral expression cassette were seeded at 50%
conﬂuence (7.5 106 cells per plate) in 10 cm cell culture plates and grown to
conﬂuence overnight. The next day, the cell layer was washed twice with fresh
medium, aspirated and scraped. The total volume was adjusted to 150 ml with fresh
medium for a density of 105 cells ml 1and pipetted up and down to break up
clumps until a homogenous cell suspension was obtained. Dispersion and integrity
of cells was conﬁrmed by brightﬁeld microscopy.
Software availability. Scientiﬁc Python is freely available at https://www.scipy.
org. AFNI is a freely available at https://afni.nimh.nih.gov/afni. The customized
scripts used for processing the data in this paper are available from the
corresponding author upon reasonable request.
Data availability. Full sequences for all plasmids are provided in Supplementary
Tables 1–8. The data that support the ﬁndings of this study are available from the
corresponding author upon reasonable request.
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